GlaxoSmithKline

By Jonah Comstock November 7, 2018
By and large, Q3 2018 was a slow and steady quarter for pharma moves in digital health, at least in terms of publicly disclosed operations. At events during the quarter, the likes of Johnson & Johnson, AstraZeneca, Novartis and Sanofi discussed digital therapeutics and expressed a healthy mixture of skepticism and enthusiasm for the space. “These technologies have a tremendous opportunity to...
23andMe lands $300 million investment from GlaxoSmithKline

23andMe kits at a Beverly Hills event in 2017. Credit: Matt Winkelmeyer, Getty Images

By Bernie Monegain July 25, 2018
23andMe on Wednesday announced that GlaxoSmithKline has invested $300 million to gain exclusive access to the genetic testing startup’s DNA database.  The deal comes as GlaxoSmithKline amid reports that GSK is weighing the possibility of a company breakup and investors contending that synergies between consumer markets and big pharma are inherently limited and that GSK’s pharmaceuticals business...
By Dave Muoio July 19, 2018
Earnings reports shared by neurostimulation and digital medicine company NeuroMetrix during a Q2 investors’ call showed a slight drop in total revenue as the company is preparing to place its marketing weight behind the launch of its updated wearable pain relief product, Quell. However, the company remained profitable during the quarter thanks to sales of its other product, DPNCheck. Dr. Shai N....
By Dave Muoio October 9, 2017
Launchpad’s new arrivals. San Francisco-based accelerator Launchpad Digital Health has added eight new digital health startups to its 12-month program: Agathos, a care variation and cost measurement platform; Addicaid, a virtual addiction recovery program; Elemeno Health, virtual coach software for healthcare teams; Happy Couple, a daily relationship bonding app; Mentia, a therapeutic support...
By Jonah Comstock August 3, 2017
GlaxoSmithKline has made a hire signaling its commitment to digital health. Karenann Terrell, former Chief Information Officer at Walmart, will start at GSK in the newly created role of Chief Digital and Technology Officer. “The impact of technology on the healthcare industry is accelerating and requires us to rethink our approach,” CEO Emma Walmsley said in a statement. “As a member of the...
By Jonah Comstock September 23, 2016
When Apple announced ResearchKit in March 2015, and unveiled the first five apps to test-drive the company’s new approach to clinical research, the announcement made a big splash. And indeed, in the weeks following, those apps posted incredible recruitment figures: for instance, Parkinson’s emPower study saw 5,500 sign-ups by day two and ended up with more than 18,000 participants.  But there...
By Heather Mack August 2, 2016
UK-based pharmaceutical giant GlaxoSmithKline has partnered with South San Francisco-based Verily to create Galvani Bioelectronics – a joint venture to develop implantable bioelectric medicines, a branch of medicine that works to fight diseases by targeting electrical signals in the body. Galvani, owned 55 percent by GSK and 45 percent by Verily (formerly known as Google Life Sciences) will have...
By Jonah Comstock July 18, 2016
GlaxoSmithKline has launched the ResearchKit app that it told Buzzfeed it was working on more than a year ago, making it the first pharma company to get a ResearchKit study off the ground. The study is called PARADE, which the company says stands for Patient Rheumatoid Arthritis Data in the Real World. "We are the first in our industry to use Apple’s ResearchKit as part of our research, this time...
By MHN Staff April 14, 2016
As we do every quarter, MobiHealthNews has rounded up our Q1 2016 coverage into a handful of longform stories. This section is on pharma. Skip ahead using these links to read Q1 digital health news roundups about providers, payers, M&A and funding. Novartis Novartis announced a partnership with Qualcomm Life, a subsidiary of Qualcomm, to develop a connected version of its inhaler, Breezhaler...
By MHN Staff April 8, 2016
More and more, pharma companies are making real bets in digital health, and reorganizing their businesses to put some power behind those efforts. The space is, in some ways, quieter than it was this time last year, but there’s reason to believe that quiet is a calm before a storm of activity, driven more by pharma’s tendency to keep early-stage projects close to the chest than by a lack of...